This letter provides constructive feedback on the recent study titled “Efficacy and Safety of Anti-CGRP Monoclonal Antibodies in Prevention of Chronic Migraine: A Bayesian Network Meta-analysis” by Mundot Puliappadamb Haridas et al. The feedback highlights areas for improvement, including the utilization of the GRADE framework, comprehensive discussion of limitations, clarification of methodological choices, adherence to reporting guidelines, and accurate differentiation of previous studies. Implementing these suggestions would enhance the quality and impact of the study, benefiting the field of migraine research and clinical practice.